Brokerages Anticipate Opiant Pharmaceuticals Inc (OPNT) to Post ($0.11) EPS

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $44.50 for the company and are predicting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given Opiant Pharmaceuticals an industry rank of 120 out of 255 based on the ratings given to its competitors.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 4th. Cantor Fitzgerald set a $32.00 price objective on shares of Opiant Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th.

An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Northern Trust Corp acquired a new position in Opiant Pharmaceuticals Inc (NASDAQ:OPNT) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 24,372 shares of the technology company’s stock, valued at approximately $350,000. Northern Trust Corp owned 0.86% of Opiant Pharmaceuticals at the end of the most recent reporting period. 4.76% of the stock is owned by institutional investors and hedge funds.

Shares of OPNT opened at $17.35 on Wednesday. The firm has a market cap of $60.18 million, a PE ratio of 50.76 and a beta of -0.04. Opiant Pharmaceuticals has a 12-month low of $12.75 and a 12-month high of $48.00.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Thursday, August 9th. The technology company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.55. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 471.43%. The company had revenue of $3.15 million during the quarter, compared to analyst estimates of $2.10 million. sell-side analysts predict that Opiant Pharmaceuticals will post -5.4 EPS for the current fiscal year.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Recommended Story: What does RSI mean?

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply